DOWNSTREAM PROCESSING FEATURED ARTICLES
Pelican Products, Inc., created the new Pelican BioPharma™ Division that will usher in the next generation of cold chain products, logistics and service.
-
New Biofuel Process Dramatically Improves Energy Recovery
A new biofuel production process created by Michigan State University researchers produces 20 times more energy than existing methods.
-
AB SCIEX And Indigo Team Up To Accelerate Adoption Of Next-Generation Mass Spectrometry For Clinical Research, Forensic Toxicology And Clinical Trials AB SCIEX and Indigo BioSystems recently announced an agreement to jointly market mass spectrometry solutions that streamline data acquisition and automate data review to ensure high quality results in clinical research and forensic toxicology as well as pre-clinical and clinical trials of new drugs.
-
Critical Innovation Bioprocessing Trends For 2014
How the most critical innovations will affect the industry future with the efforts to reduce the costs of manufacturing a biologic, according to the 10th Annual Report and Survey of Biopharmaceutical Manufacturers.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
Important Parameters For Packing Nuvia HR-S Resin At Process Scale
Process-scale production typically involves more than one column. The packing quality of each column affects the efficiency of the whole workflow and is an important validation criterion.
-
Optimized Purity And Recovery Of A Monoclonal Antibody Using Mixed-Mode Chromatography Media
Monoclonal antibodies (mAbs) remain a predominant class of therapeutic protein products on the market because of their wide range of applications in disease treatment and diagnosis. Over the years, upstream technology advancements have helped improve the titer of target antibodies, from merely 1 g/L two decades ago to 10–13 g/L in fed-batch processes and up to 25 g/L in perfusion cultures today (Gronemeyer et al. 2014).
-
Improving DNA Removal from Bioprocess Purification Processes
Many new biological drug products produced using recombinant DNA technology, such as monoclonal antibodies, are produced in cell culture. Because therapeutic proteins such as monoclonal antibodies are produced in cell culture, impurities can result from the host cells, or cell substrates. By 3M Purification Inc.
-
Examining Column Reproducibility During Method Development In Clinical Labs
In this study demonstrates how the HSS T3 stationary phase is a reliable stationary phase, as three batches made over a five-year span provide comparable results.
-
Agilent Microarray Grant Application Support White Paper This guide offers an overview of Agilent’s microarray and SureSelect product offerings with ordering details to assist researchers with the details of grant submission.
-
Single-Use Connections Advance Aseptic Processing
John Boehm discusses how single-use connections advance aseptic processing and create increased process flexibility and reliability while reducing costs.